These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 15347309

  • 1. Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.
    Bergqvist D.
    Eur J Haematol; 2004 Oct; 73(4):227-42. PubMed ID: 15347309
    [Abstract] [Full Text] [Related]

  • 2. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 3. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug 24; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 4. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL.
    J Am Coll Cardiol; 2005 Jan 04; 45(1):1-9. PubMed ID: 15629364
    [Abstract] [Full Text] [Related]

  • 5. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.
    Rosencher N.
    Anaesthesia; 2004 Aug 04; 59(8):803-10. PubMed ID: 15270973
    [Abstract] [Full Text] [Related]

  • 6. Ximelagatran: a new type of oral anticoagulant.
    Kwok L, Molckovsky D, Boucher M.
    Int J Technol Assess Health Care; 2005 Aug 04; 21(4):480-6. PubMed ID: 16262971
    [Abstract] [Full Text] [Related]

  • 7. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ, Frison L, Weaver D, Wilcox RG, Bylock A, Emanuelsson H, Held P, Oldgren J.
    Am Heart J; 2008 Feb 04; 155(2):382-7. PubMed ID: 18215612
    [Abstract] [Full Text] [Related]

  • 8. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N, Hiroe K, Kawamura M.
    Thromb Haemost; 2010 Sep 04; 104(3):504-13. PubMed ID: 20664909
    [Abstract] [Full Text] [Related]

  • 9. Ximelagatran: a new oral anticoagulant.
    Francis CW.
    Best Pract Res Clin Haematol; 2004 Mar 04; 17(1):139-52. PubMed ID: 15171963
    [Abstract] [Full Text] [Related]

  • 10. Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin.
    Fernlöf G, Sjöström BM, Lindell KM, Wall UE.
    Blood Coagul Fibrinolysis; 2009 Dec 04; 20(8):667-74. PubMed ID: 19741508
    [Abstract] [Full Text] [Related]

  • 11. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov 04; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep 04; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 13. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R, Tran M, Gore JM, Spencer FA.
    Am Heart J; 2005 Jul 04; 150(1):19-26. PubMed ID: 16084146
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of ximelagatran.
    Wolzt M, Sarich TS, Eriksson UG.
    Semin Vasc Med; 2005 Aug 04; 5(3):245-53. PubMed ID: 16123911
    [Abstract] [Full Text] [Related]

  • 15. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec 04; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 16. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S, Giansante C.
    Ital Heart J Suppl; 2004 Sep 04; 5(9):705-11. PubMed ID: 15568608
    [Abstract] [Full Text] [Related]

  • 17. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S, Diamond GA, Weintraub WS.
    J Am Coll Cardiol; 2005 Dec 06; 46(11):1986-95. PubMed ID: 16325029
    [Abstract] [Full Text] [Related]

  • 18. Ximelagatran: pharmacokinetics and pharmacodynamics of a new strategy for oral direct thrombin inhibition.
    Kereiakes DJ.
    Rev Cardiovasc Med; 2004 Dec 06; 5 Suppl 5():S4-11. PubMed ID: 15619615
    [Abstract] [Full Text] [Related]

  • 19. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug 06; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 20. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
    Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S, THRIVE III Investigators.
    Br J Haematol; 2006 Apr 06; 133(1):68-77. PubMed ID: 16512831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.